ClinicalTrials.Veeva

Menu

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (INTRO)

R

Radboud University Medical Center

Status and phase

Completed
Phase 1

Conditions

Recurrent Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Treatments

Biological: UCB-NK cells
Drug: Chemotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT03539406
NL60937.000.17

Details and patient eligibility

About

This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex vivo-generated allogeneic natural killer (NK) cells with or without preceding non-myeloablative conditioning chemotherapy.

Full description

This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex vivo-generated allogeneic natural killer (NK) cells with or without preceding non-myeloablative conditioning chemotherapy.

This study is a phase I safety and feasibility study in a series of 12 patients who are suffering from recurrent ovarian, fallopian tube or primary peritoneal cancer. Prior to NK cell infusion, a laparoscopy is performed to place a catheter in the peritoneal cavity. The first cohort of three patients will receive an intraperitoneal infusion of allogeneic UCB-NK cells generated ex vivo from CD34+ hematopoietic progenitor cells obtained from an allogeneic UCB unit without a preparative regimen. In the second group of three patients the same UCB-NK cell dosage will be given with a preparative regimen of four days non-myeloablative immunosuppressive conditioning regimen with cyclophosphamide and fludarabine (CyFlu). If no severe toxicity is seen in these 6 patients, an extension cohort of 6 patients will be included to answer the secondary objective.

Enrollment

11 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients suffering from their second recurrence of ovarian, fallopian tube or primary peritoneal cancer, with an elevated serum level of CA-125 on two successive time points with 28 days in between, reaching a value of more than 2 times nadir and above 35 U/ml without gastrointestinal symptoms.
  • Able to undergo laparoscopic IP port placement and IP treatment administration
  • Adequate organ function
  • Age 18 years or older
  • Age under 76 years.
  • Karnofsky performance status >70% (see appendix 2)
  • Life expectancy > 6 months
  • At least 28 days after last anti cancer treatment, before start of preparative regimen
  • Written informed consent
  • Availability of a partially HLA-matched UCB unit

Exclusion criteria

  • Patients on immunosuppressive drugs
  • Patients with active infections (viral, bacterial or fungal) that requires specific therapy. Acute anti-infectious therapy must have been completed within 14 days prior to study treatment
  • Laparoscopic adhesion score >4 out of 9.
  • Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease (appendix 4)
  • Severe pulmonary dysfunction (CTCAE III-IV) (appendix 4)
  • Severe renal dysfunction (MDRD<50) (appendix 4)
  • Severe hepatic dysfunction (serum bilirubin or transaminases > 3 times normal level) (appendix 4)
  • Severe neurological or psychiatric disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

11 participants in 2 patient groups

NK-cells without preparative regimen
Experimental group
Description:
NK-cells without preparative regimen
Treatment:
Biological: UCB-NK cells
NK-cells with preparative regimen
Experimental group
Description:
NK-cells with preparative regimen
Treatment:
Drug: Chemotherapy
Biological: UCB-NK cells

Trial contacts and locations

1

Loading...

Central trial contact

Janneke Hoogstad-van Evert, MSc.; Harry Dolstra, associate professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems